Vancouver, British Columbia–(Newsfile Corp. – March 2, 2021) – NeonMind Biosciences Inc. (CSE: NEON) (OTC Pink: NMBDF) (FSE: 6UF) (“NeonMind“) is pleased to announce that it has filed four new provisional patent applications with the United States Patent and Trademark Office to protect initial data obtained during NeonMind’s preclinical trial. The provisional patent applications include data…

Source

Previous articlePharmaTher Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine in the Treatment of Lou Gehrig’s Disease
Next articlePsyched Wellness Provides Update on Pre-Clinical Trial of Its Muscimol Extract AME-1